Hutchmed (HCM) announced that it will receive a $20M milestone payment from its partner Takeda (TAK), triggered by reaching over $200M in sales of Fruzaqla for metastatic colorectal cancer, or CRC. CRC is the second most common cause of cancer-related deaths in the U.S. There are approximately 840,000 new cases of CRC each year across the U.S,, Europe and Japan. Takeda delivered $203M in net sales of Fruzaqla in the nine months ended September. This $20M payment will be the first ever commercial milestone payment received by Hutchmed. Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau, and markets under the Fruzaqla brand name. It received approval in the U.S. in November 2023, in the EU in June, in Switzerland in August, in Canada, Japan and the United Kingdom in September and in Argentina, Australia and Singapore in October. Regulatory applications are progressing in many other jurisdictions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCM:
- Hutchmed announces results from SAVANNAH trial
- Hutchmed, Takeda receive Japan MHLW approval to manufacture and market Fruzaqla
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
